Kathryn E. Falberg, Director at Aimmune Therapeutics, Inc. (AIMT), bought 25,000 shares at $16.00 ($400K) on 2015-08-11, disclosed to the SEC on 2015-08-11.
Open-market purchase of $400k AIMT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| TTD | SELL | 2024-03-12 | $16.9M | — | Filing → |
| NUVB | BUY | 2022-12-05 | $789K | — | Filing → |
| TTD | SELL | 2021-11-23 | $32.5M | — | Filing → |